Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. - sprookjes - yvandenbroek - TriplyDB

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.

http://www.wikidata.org/entity/Q35543657

about

Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies Reactivation of telomerase in cancer The function, regulation and therapeutic implications of the tumor suppressor protein, PML Targeting the Checkpoint to Kill Cancer Cells Telomere biology: Rationale for diagnostics and therapeutics in cancer RNase P protein subunit Rpp29 represses histone H3.3 nucleosome deposition The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype Noncanonical views of homology-directed DNA repair Telomere elongation chooses TERRA ALTernatives Genetic Inactivation of ATRX Leads to a Decrease in the Amount of Telomeric Cohesin and Level of Telomere Transcription in Human Glioma Cells Epigenetic Regulation of Telomere Maintenance for Therapeutic Interventions in Gliomas.Withaferin-A kills cancer cells with and without telomerase: chemical, computational and experimental evidences.Telomere Biology-Insights into an Intriguing Phenomenon.Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop.Timeless protection of telomeres.Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma.Mre11 and Blm-Dependent Formation of ALT-Like Telomeres in Ku-Deficient Ustilago maydis.Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.Swi1Timeless Prevents Repeat Instability at Fission Yeast Telomeres.Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase New Genetics and Genomic Data on Pancreatic Neuroendocrine Tumors: Implications for Diagnosis, Treatment, and Targeted Therapies.Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma.Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer.Future directions in the treatment of osteosarcoma.Long Noncoding RNAs in Cancer Pathways ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability.Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas Telomeric RNAs are essential to maintain telomeres.Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX.A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors SMARCAL1 Resolves Replication Stress at ALT Telomeres.Nuclear Noncoding RNAs and Genome Stability.ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.Telomeres in ICF syndrome cells are vulnerable to DNA damage due to elevated DNA:RNA hybrids Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.Efficacy of ATR inhibitors as single agents in Ewing sarcoma.Stop pulling my strings - what telomeres taught us about the DNA damage response.Telomeric repeat-containing RNA TERRA: a noncoding RNA connecting telomere biology to genome integrity Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma Molecular Pathways: Targeting ATR in Cancer Therapy

P2860

Q26744271-8AB2CC07-87AB-4144-9552-AB13C76AD6A5 Q26769014-95BD5644-A796-4015-BA5E-27DF7A96C193 Q26779358-D77CA602-E901-4B9F-A9E5-C7E1FB8BAB08 Q26795781-9CEB7BB0-8431-493C-91D8-EC1D220F6ADF Q26796323-7273A475-9F2E-47DA-8E0D-C071CB924F4F Q27306288-23725B5D-8808-48FA-93A6-362C2B2CCC4C Q28071562-3C1703DA-06C9-4879-A331-F2A25879BA1F Q28080032-2D57351A-DDB5-4314-B039-1C66B6BF181E Q28083799-19204787-B52F-490E-B034-AA5C2C8077D6 Q28118722-DEA0FF13-DBDC-4056-998B-882CD6BAEDB3 Q33737472-095009BC-E382-4E07-9F8D-57EFB6124AEE Q33815938-CEE2732D-9616-4BA8-ABB6-AE639AA06160 Q33855946-20708066-66F5-428A-AB8C-AB1DCC6F59A4 Q33872384-DD608C68-C044-41C1-9F98-507D16F2947D Q34521770-81AAC0F5-E819-484A-89ED-DD24DD6A2714 Q34680693-629FA2C0-D992-4D15-BEE1-EFCFFDCDCB70 Q35817236-9D32FA31-9130-4024-B3D9-A293E525C4AB Q35927459-54B73178-EC10-450C-A673-800E6FC25ADE Q35962436-7E2DFB63-869E-4E57-B93B-BB8B42B82165 Q36075291-E8229B79-9623-4255-A8FB-7C1895D7BEFF Q36085145-6515FCC5-8E3D-463E-BDBB-CFD3C61214E5 Q36309545-B44818E6-0B08-40A4-997B-EEE1649073B8 Q36378105-FA81BAE1-4984-45D5-B830-CBCD85C79101 Q36600800-E19BC8EA-ED74-498E-8862-2AE82D2C99D9 Q36796798-2E550172-D213-4EF0-8BCC-EC25BE4D895B Q37008597-1AA8AEE3-8FFF-4C52-BBC0-BF9B17E7F99B Q37086042-BCDE1A6B-9ABC-4248-85DE-89CCC88C28EF Q37191635-CA3BE88C-90E5-4A5D-9F55-35080BE95FF3 Q37220140-688D56B6-E6F6-4E50-867A-CDAB1DA49B28 Q37268724-0EBD590B-95DB-40B4-9F90-5DCB52E99DBC Q37312254-72C6830B-68AA-4F7C-B6E6-853BEB2697C6 Q37471101-0C734DDA-D13B-4EA3-86C2-88A711A11CFC Q37508792-C5FEA470-D847-437A-B071-F941A4C0F3E3 Q37617948-A741C5A0-2CFE-4BCE-B493-2F2D5A565792 Q37634102-01F369DD-A00B-4EAB-A089-D7232C85E9B4 Q37644764-86087EFF-02F6-4D28-9211-739B576A6266 Q37742751-D2CFD151-DC18-414A-A727-4A4518C35C45 Q38450799-65BF6DA7-EE45-4945-B21D-80157E2D9AC6 Q38453759-23F6E2E0-95CF-4063-BC08-7F00DC79F483 Q38585436-53DC3382-0E68-4A33-8066-95905733C78E

P2860

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.

http://www.wikidata.org/entity/Q35543657

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Alternative lengthening of tel ...... ersensitive to ATR inhibitors.

@ast

Alternative lengthening of tel ...... ersensitive to ATR inhibitors.

@en

type

label

Alternative lengthening of tel ...... ersensitive to ATR inhibitors.

@ast

Alternative lengthening of tel ...... ersensitive to ATR inhibitors.

@en

prefLabel

Alternative lengthening of tel ...... ersensitive to ATR inhibitors.

@ast

Alternative lengthening of tel ...... ersensitive to ATR inhibitors.

@en

P1433

Q35543657-E545DF3F-DB36-44CA-A4B4-779520E36FCA

P1476

Q35543657-2AE4855F-3BBB-4C29-A479-0615B63C290A

P2093

Q35543657-1B76E1FA-BA60-42BA-9D7A-73CCB14FFFD8

Q35543657-383AABF5-35B2-4C30-BBB1-0CA728E847CC

Q35543657-4EA74FFD-EEFF-455D-A5AA-178141B792CD

Q35543657-4F658F4B-3321-48C8-BE70-177EB847EB2C

Q35543657-548E9F3F-2B6B-49C9-B865-54DD5F153A93

Q35543657-75374700-6A2A-42A0-9FA0-95FA40A2F231

Q35543657-7576F3BC-13F2-4466-A49E-8CD7E1B12AD9

Q35543657-9708C342-B138-4723-99BF-88B575CA0982

Q35543657-9AD7113F-4C22-4458-96D3-A62E553F2C4D

Q35543657-D6EA1A79-08E5-4F70-AD4D-2ED3E529C5E7

P2860

Q35543657-084F3BC6-0A4E-4E02-8252-8074AD25A44A

Q35543657-09957BDD-0EF4-422D-A602-297A362E5AF9

Q35543657-0D3EA211-2082-4C42-BB61-B0A315208441

Q35543657-14621944-E961-48FB-8F4E-81640A032B36

Q35543657-1C3C741E-2DED-48D9-9C60-7A04BBE95AD6

Q35543657-21F27562-F7CB-455A-A763-5AC99C22CB1E

Q35543657-223FB271-1745-4D3F-8D60-50145ACB7392

Q35543657-26F4A55B-C858-4EEB-BA16-1E229F7D28CC

Q35543657-35FC1057-46E6-42B6-9A26-F6E3AE03126A

Q35543657-40DA5A69-9D81-4334-BDF0-25DC8DF0023E

P304

Q35543657-D05BD715-37E2-46D4-80FD-BB981D50C954

P31

Q35543657-6A95AEF7-CBDA-4C45-B940-5EA3725A8C4D

P356

Q35543657-2E37A53D-DABE-49B1-9F9F-94B6B144A610

P407

Q35543657-56F4A0A8-8EA8-4603-B042-74C10208BC4C

P433

Q35543657-A2736B38-ED5F-41FE-9022-C7DB72F78C81

P478

Q35543657-4796123C-5D27-4DAD-AFF9-64D6AC6EE6E9

P50

Q35543657-2D0717E9-BED1-4DB9-8834-617E7426185E

Q35543657-8C7F2D81-26F3-46AD-9B27-0CDB286DD49B

P577

Q35543657-FBDDDCD7-D9F3-44EF-9750-A7797AB571C1

P698

Q35543657-9346A2EF-97C3-4DFE-9BC9-1E93EB47306B

P932

Q35543657-762F8B7D-9224-4167-84CD-641836AC1915

P356

SCIENCE.1257216

P1433

P1476

Alternative lengthening of tel ...... persensitive to ATR inhibitors

@en

P2093

Alysia R Bryll

http://www.w3.org/2001/XMLSchema#string

Cyril H Benes

http://www.w3.org/2001/XMLSchema#string

Daniel A Haber

http://www.w3.org/2001/XMLSchema#string

Francesca Bersani

http://www.w3.org/2001/XMLSchema#string

Hiroaki Wakimoto

http://www.w3.org/2001/XMLSchema#string

Kelli E Cox

http://www.w3.org/2001/XMLSchema#string

Lee Zou

http://www.w3.org/2001/XMLSchema#string

Mario L Suvà

http://www.w3.org/2001/XMLSchema#string

Maya Jeitany

http://www.w3.org/2001/XMLSchema#string

Neil J Ganem

http://www.w3.org/2001/XMLSchema#string

P2860

ATR kinase activity regulates the intranuclear translocation of ATR and RPA following ionizing radiation

The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins

Purification of proteins associated with specific genomic Loci

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes

RPA regulates telomerase action by providing Est1p access to chromosome ends.

Telomeric repeat containing RNA and RNA surveillance factors at mammalian chromosome ends

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Replication protein A: a heterotrimeric, single-stranded DNA-binding protein required for eukaryotic DNA metabolism

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

P304

273-277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCIENCE.1257216

http://www.w3.org/2001/XMLSchema#string

P407

P433

6219

http://www.w3.org/2001/XMLSchema#string

P478

347

http://www.w3.org/2001/XMLSchema#string

P50

Francois Boussin

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25593184

http://www.w3.org/2001/XMLSchema#string

P932

4358324

http://www.w3.org/2001/XMLSchema#string